Nemaura Medical Firmly Positioned in Growing Diabetes Tech Market

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS 

• Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes
• NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor
• Company recently completed initial shipment to UK licensee

While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical NMRD, a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech market with sugarBEAT(R) – a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help diabetes patients manage glucose levels. 

Diabetes is a significant concern in the United States, according to a report released by the Center for Disease Control (“CDC”) that provides statistics across…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Image credit: Diabetes by Nick Youngson CC BY-SA 3.0 Pix4free

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.